A mouse study published in the European Journal of Pharmacology reports that the GLP-1 receptor agonist dulaglutide reduced markers of liver injury in a diabetic mouse model of metabolic dysfunction-associated steatotic liver disease. The authors say the findings support further investigation of the drug in MASLD, not that its use in the condition is established.

The work was carried out entirely in db/db mice, a strain used to model diabetes and fatty liver, and the abstract describes no human testing. Dulaglutide is a glucagon-like peptide-1 receptor agonist already approved for diabetes treatment, and MASLD is a chronic liver disease the authors describe as spanning simple fat accumulation, steatohepatitis, fibrosis and cirrhosis.

Ten weeks and a death pathway

The animals were treated for 10 weeks, after which the researchers assessed liver function, tissue histopathology, inflammation and fibrosis, measured ferroptosis-related markers and ran a lipidomics analysis of hepatic lipid profiles.

Ferroptosis is a form of cell death linked to iron accumulation and lipid peroxidation, and it is the mechanism this study was built around. The question was not simply whether the liver looked better but whether dulaglutide was acting on that specific pathway.

Key results

Dulaglutide reduced serum ALT and AST, two standard blood measures of liver injury, and altered expression of the ferroptosis-related proteins ACSL4 and GPX4. Reactive oxygen species staining and iron quantification indicated that treated animals showed less oxidative stress and less iron accumulation than untreated db/db mice.

Treatment was also associated with higher GSH and Nrf2 and lower MDA and 4-HNE, which the authors interpret as reduced lipid peroxidation. The lipidomics analysis showed what the paper calls extensive remodeling of the hepatic lipid profile, and inflammatory and fibrotic marker expression was reduced.

Limitations

This was an animal study in a single genetic mouse strain, and the abstract reports no human data. It also gives no group sizes, no dose and no effect sizes, which means the magnitude of every change above is unknowable from what has been published.

ALT, AST and GPX4 are surrogate measures rather than clinical outcomes. Moving them is not the same as helping a person with MASLD, and the paper does not claim otherwise.

The distance to a patient

The authors conclude that dulaglutide modulates ferroptosis-related markers, inflammation and fibrosis in this model, and describe it as a potential therapeutic option for MASLD. Whether any of that carries into human liver disease remains untested in this paper.